Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biogenerics: potential benefits and obstacles.

Jeannette Y Wick1, Guido R Zanni

  • 1National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
|April 1, 2006
PubMed
Summary

Generic substitution offers cost savings for prescription drugs. However, despite patent expirations for biologics, no generic versions (biogenerics) are approved due to scientific and safety challenges in replicating complex molecules.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bereavement and Loss: Understanding Grief in Older People.

The Senior care pharmacist·2024
Same author

Telehealth: Moving Older People Along the Adoption Trajectory.

The Senior care pharmacist·2023
Same author

Insomnia Is Not a Normal Part of Aging: The Challenges of Safely and Effectively Managing Insomnia in Older People.

The Senior care pharmacist·2023
Same author

Treating Erectile Dysfunction with Prescription Medications & Natural Products: A Pharmacist's Guide.

The Senior care pharmacist·2021
Same author

Alcohol-Related Dementia: Rethink How Much You Drink.

The Senior care pharmacist·2021
Same author

Skin Tears in Older People.

The Senior care pharmacist·2020

Area of Science:

  • Pharmaceutical Sciences
  • Biotechnology
  • Drug Development

Background:

  • Generic substitution is a well-established practice in the pharmaceutical industry, leading to significant cost reductions for widely used small-molecule drugs.
  • The biologics market is experiencing rapid growth, with several high-value biologic drugs nearing or having passed patent expiration.
  • Currently, the pharmaceutical landscape lacks approved generic alternatives for biologics, commonly referred to as biogenerics.

Purpose of the Study:

  • To examine the reasons behind the absence of approved biogenerics despite patent expirations for successful biologic medications.
  • To identify the scientific and regulatory hurdles preventing the development and approval of generic biologics.

Main Methods:

  • Analysis of the scientific complexities inherent in replicating large, complex biological molecules (proteins and sugars).

Related Experiment Videos

  • Review of safety considerations associated with generic biologic products.
  • Examination of the regulatory pathways for abbreviated drug approval processes in the context of biologics.

    • Main Results:

    • Significant scientific challenges exist in precisely replicating the structure and function of large biologic molecules.
    • Safety concerns related to the immunogenicity and efficacy of potential biogenerics are major obstacles.
    • These scientific and safety issues impede the establishment of an abbreviated approval process similar to that for small-molecule generics.

    Conclusions:

    • The intricate nature of biologics presents substantial scientific and safety barriers to the development of generic versions.
    • Overcoming these challenges is crucial for enabling an abbreviated regulatory pathway for biogenerics.
    • The lack of biogenerics may limit cost-saving opportunities for patients and healthcare systems in the rapidly growing biologics market.